Roche Holding AG (RHHVF)
| Market Cap | 279.51B |
| Revenue (ttm) | 79.83B |
| Net Income (ttm) | 11.86B |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | 23.58 |
| Forward PE | 13.81 |
| Dividend | 10.98 (3.32%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 9 |
| Average Volume | 4,420 |
| Open | 329.19 |
| Previous Close | 330.52 |
| Day's Range | 323.77 - 329.19 |
| 52-Week Range | 269.80 - 354.19 |
| Beta | 0.17 |
| RSI | 55.18 |
| Earnings Date | Jul 24, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Roche presents new insights in Alzheimer's disease research across its diagnostics and pharmaceutical portfolios at AAIC
Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Confer...
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being pres...
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday.
Roche Holding AG 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Roche Holding AG in conjunction with their 2025 Q2 earnings call.
Roche Holding AG (RHHBY) Q2 2025 Earnings Call Transcript
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (del...
Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results
Roche Diagnostics showcases science-driven leadership and innovation at ADLM 2025
Lead With Us -- a promise for innovative partnerships, better insights, faster support, and improved healthcare outcomes. INDIANAPOLIS and CHICAGO , July 24, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; ...
Significant amount of U.S. investment pledged, says Roche CEO
Thomas Schinecker, CEO of Roche, discusses the company's earnings and what the pharmaceutical industry in Europe is doing to win favour with the Trump administration.
Roche eyes direct-to-patient sales in U.S. to avoid pharma middlemen
Roche considering selling drugs directly to US patients, CEO says
Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part of talks with the U.S. government, which is pressuring drugmakers to cut p...
Roche Holding Non-GAAP EPS of CHF 11.08, revenue of CHF 30.94B
Roche confirms guidance as H1 core operating profit up 6%
Swiss drugmaker Roche reported first-half operating profit up 6% on Thursday at a forecast-beating 12 billion Swiss francs ($15.15 billion) and also confirmed its full-year outlook.
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
Basel, 24 July 2025 Group sales grew by 7%1 at constant exchange rates (CER; 4% in CHF), driven by strong demand for medicines. Pharmaceuticals Division sales rose by 10% (6% in CHF), with Phesgo (bre...
The Roche Associates, Inc. Named “Top Senior Living Marketing Agency 2025”
East Longmeadow, MA, July 23, 2025 (GLOBE NEWSWIRE) -- The Roche Associates, Inc. was recently named “Top Senior Living Marketing Agency for 2025” by Elder Care Review. The Roche Associates, Inc. emer...
Roche's Itovebi combination for breast cancer gets EU nod
Roche pauses Sarepta gene therapy shipments outside the U.S.
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease
Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® pTau181 test to measure phosphorylated Tau (pTau) 181 protein which is an indicator of...
European Commission approves Roche's Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, fo...
Roche pauses shipments of Elevidys gene therapy outside the US, Bloomberg News reports
Roche Holding AG paused all shipments of the controversial gene therapy Elevidys, Bloomberg News reported on Tuesday.
Roche's Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd's capital structure for approv...
Roche COPD biologic astegolimab fails in phase 3 for COPD
Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase IIb ALIENTO (n=1,301) and the ...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease
Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolima...
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Re...